Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Chimeric antigen receptor-T (CAR ... from leukapheresis to CAR-T cell infusion. (1) T cells are isolated from the patient's peripheral blood through leukapheresis. (2) These cells are activated using ...